Literature DB >> 26969674

Sequential tests for non-proportional hazards data.

Matthias Brückner1, Werner Brannath2.   

Abstract

In clinical trials survival endpoints are usually compared using the log-rank test. Sequential methods for the log-rank test and the Cox proportional hazards model are largely reported in the statistical literature. When the proportional hazards assumption is violated the hazard ratio is ill-defined and the power of the log-rank test depends on the distribution of the censoring times. The average hazard ratio was proposed as an alternative effect measure, which has a meaningful interpretation in the case of non-proportional hazards, and is equal to the hazard ratio, if the hazards are indeed proportional. In the present work we prove that the average hazard ratio based sequential test statistics are asymptotically multivariate normal with the independent increments property. This allows for the calculation of group-sequential boundaries using standard methods and existing software. The finite sample characteristics of the new method are examined in a simulation study in a proportional and a non-proportional hazards setting.

Entities:  

Keywords:  Average hazard ratio; Group-sequential design; Log-rank test; Non-proportional hazards

Mesh:

Year:  2016        PMID: 26969674     DOI: 10.1007/s10985-016-9360-5

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  11 in total

1.  Using auxiliary time-dependent covariates to recover information in nonparametric testing with censored data.

Authors:  S Murray; A A Tsiatis
Journal:  Lifetime Data Anal       Date:  2001-06       Impact factor: 1.588

2.  A group sequential test for survival trials: an alternative to rank-based procedures.

Authors:  Z Li
Journal:  Biometrics       Date:  1999-03       Impact factor: 2.571

3.  Sequential methods for comparing years of life saved in the two-sample censored data problem.

Authors:  S Murray; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

4.  Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.

Authors:  P Bauer; M Posch
Journal:  Stat Med       Date:  2004-04-30       Impact factor: 2.373

5.  Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial.

Authors:  H Putter; M Sasako; H H Hartgrink; C J H van de Velde; J C van Houwelingen
Journal:  Stat Med       Date:  2005-09-30       Impact factor: 2.373

6.  Planning and analyzing adaptive group sequential survival trials.

Authors:  Gernot Wassmer
Journal:  Biom J       Date:  2006-08       Impact factor: 2.207

7.  Nonparametric survival estimation using prognostic longitudinal covariates.

Authors:  S Murray; A A Tsiatis
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

8.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

9.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

View more
  2 in total

1.  Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.

Authors:  Jannik Feld; Andreas Faldum; Rene Schmidt
Journal:  Stat Methods Med Res       Date:  2021-10-12       Impact factor: 3.021

2.  Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.

Authors:  Robin Ristl; Nicolás M Ballarini; Heiko Götte; Armin Schüler; Martin Posch; Franz König
Journal:  Pharm Stat       Date:  2020-08-23       Impact factor: 1.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.